GBO declares its offer to the shareholders of Vigmed unconditional and completes the offer

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this announcement and in the tender offer document which has been published on GBO's website for the Offer (www.gbo-vigmed.se/en/).

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share. On 13 April 2017, the Offer consideration was increased to SEK 1.20 in cash per share.

The shares tendered in the Offer at the end of the extended acceptance period on 27 April 2017 amount to in aggregate 44,545,399 shares in Vigmed, corresponding to 67.75 percent of the total number of outstanding shares and votes in Vigmed.

As previously communicated, completion of the Offer is conditional upon, inter alia, the Offer being accepted to such extent that GBO becomes the owner of more than 90 percent of all shares in Vigmed. GBO has decided to waive this condition. Accordingly, all of the conditions for completion of the Offer have been satisfied or waived. GBO declares the Offer unconditional and will complete the Offer. Settlement in respect of shares in Vigmed duly tendered by 27 April 2017 is expected to be initiated on or about 5 May 2017.

To provide the remaining shareholders in Vigmed more time to accept the Offer, GBO has decided to further extend the acceptance period until and including 17 May 2017 at 5:00 p.m. CEST. Settlement in respect of shares in Vigmed tendered during such further extended acceptance period is expected to be initiated on or about 24 May 2017. The acceptance period will not be extended further.

Other than the shares in Vigmed acquired through the Offer as set out above, GBO does not currently own or control any shares or financial instruments that provide a financial exposure equivalent to a holding of shares in Vigmed.

" We are excited to become the main shareholder of Vigmed. As a long-term shareholder GBO intends to engage in the challenge of developing Vigmed's business and product portfolio, including to financially support Vigmed in the significant capital injections that will be required to satisfy the immediate need of liquidity and to realize Vigmed's long-term prospects. A significant majority of the shareholders have appreciated GBO's attractive offer and have now sold their shares to GBO. In order to provide the remaining shareholders of Vigmed the opportunity to benefit from GBO's offer, we have made a final extension of the acceptance period for an additional two weeks ", said Rainer Perneker, CEO of the Greiner Bio-One group.

Greiner Bio-One GmbH

For additional information, please contact:

Georg Heftberger, Chief Financial Officer, Greiner Bio-One GmbH, tel. +43 664 8841 0683

Eric Tapper, Hallvarsson & Halvarsson, tel. +46 8 407 21 80

For information and documentation regarding the Offer, please visit: www.gbo-vigmed.se/en/

This press release was submitted for publication on 3 May 2017 at 8:00 a.m. CEST.

Subscribe

Documents & Links